Literature DB >> 22806545

Different expression of S100A8 in malignant and benign gallbladder diseases.

Wei Wang1, Kai-Xing Ai, Zhou Yuan, Xin-Yu Huang, Hui-Zhen Zhang.   

Abstract

BACKGROUND: Proteomic analysis is a powerful tool for complete establishment of protein expression. Comparative proteomic analysis of human bile from malignant and benign gallbladder diseases may be helpful in research into gallbladder cancer. AIMS: Our objective was to establish biliary protein content for gallbladder cancer, gallbladder adenoma, and chronic calculous cholecystitis for comparative proteomic analysis.
METHODS: Bile samples were collected from patients with gallbladder cancer, gallbladder adenoma, and chronic calculous cholecystitis. Peptides of biliary proteins were separated by two-dimensional liquid chromatography then identified by tandem mass spectrometry.
RESULTS: Up to 544, 221, and 495 unique proteins were identified in bile samples from gallbladder cancer, gallbladder adenoma, and chronic calculous cholecystitis. Forty-three, 16, and 28 proteins with more than one unique peptide, respectively, were identified in the three groups. Among these, 30 proteins including S100A8 were overexpressed in gallbladder cancer, compared with benign gallbladder diseases. We also confirmed, by immunohistochemical analysis, that S100A8 is more abundant in tumor-infiltrating immune cells in cancerous tissue.
CONCLUSIONS: Compared with benign gallbladder diseases, consistently elevated S100A8 levels in malignant gallbladder bile and tissue indicate that gallbladder cancer is an inflammation-associated cancer. S100A8 may be a biomarker for gallbladder cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806545     DOI: 10.1007/s10620-012-2307-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

Review 1.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  Gallbladder cancer: what is an aggressive approach?

Authors:  Henry A Pitt
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

Review 3.  Population proteomics: the concept, attributes, and potential for cancer biomarker research.

Authors:  Dobrin Nedelkov; Urban A Kiernan; Eric E Niederkofler; Kemmons A Tubbs; Randall W Nelson
Journal:  Mol Cell Proteomics       Date:  2006-05-30       Impact factor: 5.911

Review 4.  Cancer proteomics: from signaling networks to tumor markers.

Authors:  R J Simpson; D S Dorow
Journal:  Trends Biotechnol       Date:  2001-10       Impact factor: 19.536

5.  Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis.

Authors:  Tim O Lankisch; Jochen Metzger; Ahmed A Negm; Katja Vosskuhl; Eric Schiffer; Justyna Siwy; Tobias J Weismüller; Andrea S Schneider; Kathrin Thedieck; Ralf Baumeister; Petra Zürbig; Eva M Weissinger; Michael P Manns; Harald Mischak; Jochen Wedemeyer
Journal:  Hepatology       Date:  2011-01-03       Impact factor: 17.425

Review 6.  S100A8 and S100A9 in inflammation and cancer.

Authors:  Christoffer Gebhardt; Julia Németh; Peter Angel; Jochen Hess
Journal:  Biochem Pharmacol       Date:  2006-07-17       Impact factor: 5.858

7.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer.

Authors:  Emanuel F Petricoin; Lance A Liotta
Journal:  Curr Opin Biotechnol       Date:  2004-02       Impact factor: 9.740

Review 8.  Proteomic analysis of human bile and potential applications for cancer diagnosis.

Authors:  Annarita Farina; Jean-Marc Dumonceau; Pierre Lescuyer
Journal:  Expert Rev Proteomics       Date:  2009-06       Impact factor: 3.940

9.  Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis.

Authors:  Chiung-Yu Chen; Wei-Lun Tsai; Hui-Chun Wu; Mei-Jywan Syu; Cheng-Chung Wu; Shu-Chu Shiesh
Journal:  Clin Chim Acta       Date:  2008-01-16       Impact factor: 3.786

10.  S100 chemokines mediate bookmarking of premetastatic niches.

Authors:  Shahin Rafii; David Lyden
Journal:  Nat Cell Biol       Date:  2006-12       Impact factor: 28.824

View more
  6 in total

Review 1.  Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.

Authors:  Fang Bao; Jiayue Liu; Haiyang Chen; Lu Miao; Zhaochao Xu; Guixin Zhang
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

2.  Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics.

Authors:  Nandini A Sahasrabuddhe; Mustafa A Barbhuiya; Shushruta Bhunia; Tejaswini Subbannayya; Harsha Gowda; Jayshree Advani; Braj R Shrivastav; Sanjay Navani; Pamela Leal; Juan Carlos Roa; Raghothama Chaerkady; Sanjeev Gupta; Aditi Chatterjee; Akhilesh Pandey; Pramod K Tiwari
Journal:  Biochem Biophys Res Commun       Date:  2014-03-20       Impact factor: 3.575

3.  The diagnostic and prognostic value of MRP8/MRP14 in intrahepatic cholangiocarcinoma.

Authors:  Guang-Zhi Jin; Wei Dong; Hui Dong; Hua Yu; Jia Chen; Wen-Long Yu; Ai-Jun Li; Wen-Ming Cong; Meng-Chao Wu
Journal:  Oncotarget       Date:  2015-11-17

4.  Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).

Authors:  André P Nicklas; Mario W Kramer; Jürgen Serth; Jörg Hennenlotter; Marie C Hupe; Daniel U Reimer; Arnulf Stenzl; Axel S Merseburger; Markus A Kuczyk; Christoph-Alexander J von Klot
Journal:  Adv Ther       Date:  2018-09-19       Impact factor: 3.845

5.  Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis.

Authors:  Annika Gauss; Peter Sauer; Adolf Stiehl; Christian Rupp; Johannes Krisam; Yvonne Leopold; Petra Kloeters-Plachky; Wolfgang Stremmel; Daniel Gotthardt
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

6.  Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.

Authors:  Tejaswini Subbannayya; Pamela Leal-Rojas; Mustafa A Barbhuiya; Remya Raja; Santosh Renuse; Gajanan Sathe; Sneha M Pinto; Nazia Syed; Vishalakshi Nanjappa; Arun H Patil; Patricia Garcia; Nandini A Sahasrabuddhe; Bipin Nair; Rafael Guerrero-Preston; Sanjay Navani; Pramod K Tiwari; Vani Santosh; David Sidransky; T S Keshava Prasad; Harsha Gowda; Juan Carlos Roa; Akhilesh Pandey; Aditi Chatterjee
Journal:  BMC Cancer       Date:  2015-11-04       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.